SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001714899-20-000042
Filing Date
2020-04-22
Accepted
2020-04-22 16:38:08
Documents
2
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14aproxy-definitiveadd.htm DEFA14A 37518
2 proxyimage31.jpg GRAPHIC 1548777
  Complete submission text file 0001714899-20-000042.txt   2170356
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38311 | Film No.: 20808298
SIC: 2836 Biological Products, (No Diagnostic Substances)